$Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBACCA) nested within a compassionate use program$

Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBACCA) nested within a compassionate use program

Bibliographic Details
Main Authors:	Adenis, Antoine, de la Fouchardiere, Christelle, Paule, Bernard, Burtin, Pascal, Tougeron, David, Wallet, Jennifer, Dourthe, Louis-Marie, Etienne, Pierre-Luc, Mineur, Laurent, Clisant, Stéphanie, Phelip, Jean-Marc, Kramar, Andrew, Andre, Thierry
Format:	Online
Language:	English
Published:	BioMed Central 2016
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4936193/

Similar Items

Erratum to: Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program
by: Adenis, Antoine, et al.
Published: (2016)

Regorafenib: Adding to the Armamentarium for Refractory Colorectal Cancer and GIST
by: Roman, Danielle, et al.
Published: (2013)

Regorafenib as Salvage Treatment in Korean Patients with Refractory Metastatic Colorectal Cancer
by: Kim, Seung Tae, et al.
Published: (2015)

Compassionate Care
by: Post, Stephen G., et al.
Published: (2012)

Compassionate Conversations
by: Gardner, Sharryn, et al.
Published: (2014)

The compassionate organisation
by: Poul Erik Flyvholm, Jørgensen, et al.
Published: (2015)

Study protocol of REGOSARC trial: activity and safety of regorafenib in advanced soft tissue sarcoma: a multinational, randomized, placebo-controlled, phase II trial
by: Brodowicz, Thomas, et al.
Published: (2015)

The design of compassionate care
by: Crawford, Paul, et al.
Published: (2014)

Compassionate ethics for clinics
by: Kim, Tae-Il
Published: (2013)

Compassionate use of cell products
by: de Santis, Gil Cunha, et al.
Published: (2013)

Ethics review in compassionate use
by: Jan Borysowski, et al.
Published: (2017-07-01)

Compassionate use of orphan drugs
by: Hyry, Hanna I., et al.
Published: (2015)

Predictive Value of Clinical Judgment of Tumour Progression in Phase II Trials
by: Kotecki, Nuria, et al.
Published: (2012)

Clinical complete responders to definite chemoradiation or radiation therapy for oesophageal cancer: predictors of outcome
by: Adenis, Antoine, et al.
Published: (2013)

Nurses' Perspectives on Delivering Compassionate Care
by: Oluyomi, Zoe
Published: (2014)

Compassionate conservatism vs Bush doctrine
by: Soltani, Fakhreddin, et al.
Published: (2010)

Kindling Kindness for Compassionate Disaster Management
by: Johal, Sarb
Published: (2015)

Visionary planning for a compassionate era
by: Robert, Theobald
Published: (1994)

Clinical activity of regorafenib in PDGFRA-mutated gastrointestinal stromal tumor
by: Grellety, Thomas, et al.
Published: (2015)

Regorafenib treatment for advanced, refractory gastrointestinal stromal tumor: a report of the UK managed access program
by: Kollàr, Attila, et al.
Published: (2014)

Tumour pharmacodynamics and circulating cell free DNA in patients with refractory colorectal carcinoma treated with regorafenib
by: Wong, Andrea Li Ann, et al.
Published: (2015)

Regorafenib assessment in refractory advanced colorectal cancer: RegARd-C study protocol
by: Hendlisz, Alain, et al.
Published: (2015)

Critical appraisal of the use of regorafenib in the management of colorectal cancer
by: Festino, Lucia, et al.
Published: (2013)

Prevention and management of adverse events related to regorafenib
by: De Wit, Mieke, et al.
Published: (2013)

Pharmacologic activity and pharmacokinetics of metabolites of regorafenib in preclinical models
by: Zopf, Dieter, et al.
Published: (2016)

Meeting An Unmet Need in Metastatic Colorectal Carcinoma with Regorafenib
by: Melosky, Barbara
Published: (2016)

Molecular profiling in the treatment of colorectal cancer: focus on regorafenib
by: Yan, Yiyi, et al.
Published: (2015)

SHP-1 is a target of regorafenib in colorectal cancer
by: Fan, Li-Ching, et al.
Published: (2014)

Targeting gastrointestinal stromal tumors: the role of regorafenib
by: Schroeder, Brett, et al.
Published: (2016)

Compassionate use programmes for rare diseases: proposals for actions
by: Houÿez, François, et al.
Published: (2012)

Everolimus for Compassionate Use in Multiple Basal Cell Carcinomas
by: Eibenschutz, Laura, et al.
Published: (2013)

Are Compassionate and Self-Image Goals Comparable across Cultures?
by: Kuncewicz Dariusz, et al.
Published: (2015-12-01)

Compassionate use of experimental therapies: who should decide?
by: Zettler, Patricia J
Published: (2015)

The effects of compassionate mind training on student psychotherapists
by: Elaine, Beaumont, et al.
Published: (2017)

Compassionate education from preschool to graduate school
by: Hooria, Jazaieri
Published: (2018)

Students, inclusion, help-seeking and compassionate caring
by: Sue, Holttum
Published: (2015)

Regorafenib: Antitumor Activity upon Mono and Combination Therapy in Preclinical Pediatric Malignancy Models
by: Daudigeos-Dubus, Estelle, et al.
Published: (2015)

Proactive strategies for regorafenib in metastatic colorectal cancer: implications for optimal patient management
by: Khan, Gazala, et al.
Published: (2014)

Antagonism of Sorafenib and Regorafenib actions by platelet factors in hepatocellular carcinoma cell lines
by: D’Alessandro, Rosalba, et al.
Published: (2014)

Metastatic colorectal cancer responsive to regorafenib for 2 years: a case report
by: Kenji Yoshino, et al.
Published: (2017-08-01)